Paratek Pharmaceuticals announced the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in the United States and Europe.
NUZYRA is the company’s broad-spectrum, novel antibiotic available in both intravenous and oral formulations.
Onshoring of the manufacturing process for the tablets is the first completed step in the technology transfer process, with the active pharmaceutical ingredient (API) for NUZYRA and NUZYRA vials scheduled to be completed in 2023 and 2024, respectively.
The commercial availability of NUZYRA tablets manufactured in the United States represents the first of several steps to create an end-to-end U.S. supply chain for NUZYRA under the Project BioShield public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.